LONA Overview

LeonaBio, Inc., formerly Athira Pharma, Inc., is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The Company's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations.

Wall Street analysts forecast LONA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LONA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

LeonaBio Inc revenue for the last quarter amounts to -18.14M USD, increased 90.26

LeonaBio Inc. EPS for the last quarter amounts to -20903000.00 USD, increased 42.54

LeonaBio Inc (LONA) has 19 emplpoyees as of May 29 2026.

Today LONA has the market capitalization of 92.15M USD.